KDIGO and NICE have since updated their guidelines. Based on KDIGO 2024 and NICE 2021 guidelines, the newly constituted MACB CKD Task Force has updated their recommendations on laboratory reporting of eGFR and urine albumin, as well as to include 5-year and 2-year predicted risk of progressing to end stage kidney disease (ESKD), calculated using the kidney failure risk equation (KFRE). KFRE-predicted risk will be included in blood reports when eGFR (Chronic Kidney Disease Epidemiology Collaboration, CKD-EPI) is less than 60 ml/min/1.73 m² and where urine albumin to creatinine ratio (uACR) is measured. This will not only help predict who will have a high risk of progression to ESKD, but also to help identify individuals who need referral to nephrologists to modify the progression of kidney disease.